Outcome Data
| Patient no. | Histology | CT stage | Age (y) | Sex | Diameter on CT (cm) | Curve type | SUV | T/R | Outcome | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–14 min | 2 h | 4 h | 2 h | 4 h | |||||||||||
| 1 | NSCLC, SCC, G2 | cT3–4 N2 M0 | 56 | M | 2.2 | 1.8 | 1.9 | 1.55 | 1.88 | Progression, exitus after 0.5 mo | |||||
| 2 | HNC, SCC, G2–3 | cT4 N2c M0 | 58 | M | 2.5 | 2.3 | 2.5 | 2.80 | 2.03 | Progression, exitus after 7.5 mo | |||||
| 3 | HNC, SCC, G2 | cT3 N2b M0 | 46 | M | 3.0 | 2.6 | 2.2 | 2.2 | 1.38 | 1.50 | Local recurrence after 9 mo | ||||
| 4 | HNC, SCC, G2 | cT4 N2b M0 | 52 | M | 11.5 | 3 | 3.7 | 3.2 | 3.1 | 2.97 | 3.44 | Local recurrence after 6 mo | |||
| 5 | NSCLC, SCC, G1 | cT3 N2 M1? | 71 | M | 13.2 | 3 | 3.0 | 1.8 | 1.7 | 2.60 | 2.53 | Local recurrence after 6 mo | |||
| 6 | NSCLC, ADC, G3 | cT3 N2 M1? | 50 | F | 7.0 | 2 | 3.0 | 1.1 | 1.7 | 1.56 | 1.80 | Progression after 3 mo | |||
| 7 | HNC, SCC, G2 | cT4 N2 M0 | 45 | M | 3.9 | 3 | 3.8 | 1.8 | 1.5 | 1.29 | 1.36 | Local recurrence after 8 mo | |||
| 8 | NSCLC, ADC, Gx | cT2 N0 M0 | 70 | M | 2.8 | 2 | 2.3 | 1.2 | 1.4 | 1.10 | 1.29 | Progression after 4 mo | |||
| 9 | NSCLC, BAL, Gx | cT4 N2 M0 | 58 | M | 5.0 | 1 | 3.2 | 1.5 | 1.5 | 1.06 | 1.24 | Response | |||
| 10 | HNC, SCC, G2–3 | cT4 N2b M0 | 61 | F | 4.0 | 1 | 3.4 | 2.0 | 1.9 | 1.49 | 1.37 | Response | |||
| 11 | NSCLC, ADC, G3 | cT4 N2 M0 | 70 | F | 4.0 | 2 | 2.0 | 2.1 | 1.9 | 1.95 | 1.97 | Response | |||
| 13 | HNC, SCC, G2–3 | cT4 N0 M0 | 66 | M | 4.6 | 3 | 2.5 | 1.9 | 2.1 | 1.45 | 2.80 | Residual tumor, metastases after 4 mo | |||
| 14 | HNC, SCC, Gx | cT4 N2 M0 | 60 | M | 4.2 | 2 | 2.2 | 1.6 | 1.5 | 1.43 | 1.68 | Progression after 8 mo | |||
| 16 | HNC, SCC, Gx | cT2 N2 M0 | 50 | F | 2.9 | 1 | 2.43 | 1.14 | 0.99 | 1.20 | 1.19 | Response | |||
| 17 | HNC, SCC, G3 | cT2 N2 M0 | 66 | M | 3.0 | 3 | 2.5 | 1.7 | 1.8 | 1.44 | 1.75 | Residual tumor, metastases, exitus after 7.5 mo | |||
| 19 | NSCLC, SCC, Gx | cT4 N3 M1? | 60 | M | 3.0 | 2 | 2.6 | 1.3 | 1.4 | 2.12 | 3.29 | Local recurrence and metastases after 8 mo | |||
| 20 | NSCLC, ADC, G3 | cT3 N3 M0 | 58 | F | 4.0 | 2 | 2.8 | 2.1 | 2.0 | 2.3 | 3.76 | Residual tumor, metastases | |||
| 21 | HNC, SCC, G2–3 | cT3 N2 M0 | 63 | M | 2.3 | 2 | 1.8 | 1.5 | 1.4 | 1.30 | 1.17 | Response | |||
| 23 | HNC, SCC, G2 | cT2 N2c M0 | 49 | M | 4.0 | 3 | 1.3 | 1.3 | 1.4 | 1.38 | 1.53 | Response | |||
| 24 | HNC, SCC, G2 | cT3 N2c M0 | 52 | M | 5.7 | 2 | 1.9 | 1.3 | 1.4 | 1.06 | 1.24 | Response | |||
| 25 | HNC, SCC, G1 | cT3 N2b M0 | 65 | M | 4.2 | 1 | 2.1 | 1.7 | 1.7 | 1.47 | 1.53 | Response | |||